Merck Expects 2024 Sales Of $63.6B-$64.1B Compared To Prior Guidance Of $63.4B-$64.4B And Consensus Of $64.162B
Merck & Co., Inc. -0.31%
Merck & Co., Inc. MRK | 99.17 | -0.31% |
Full-Year 2024 Financial Outlook
The following table summarizes the company's full-year financial outlook.
| Full Year 2024 | ||
| Updated | Prior | |
| Sales | $63.6 to $64.1 billion | $63.4 to $64.4 billion |
| Non-GAAP Gross margin | Approximately 81% | Approximately 81% |
| Non-GAAP Operating expenses2 | $27.8 to $28.3 billion | $26.8 to $27.6 billion |
| Non-GAAP Other (income) expense, net | Approximately $100 million expense | Approximately $350 million expense |
| Non-GAAP Effective tax rate | 16.0% to 17.0% | 15.5% to 16.5% |
| Non-GAAP EPS | $7.72 to $7.77 | $7.94 to $8.04 |
| Share count (assuming dilution) | Approximately 2.54 billion | Approximately 2.54 billion |
